Bluejay Diagnostics, Inc. (BJDX): Price and Financial Metrics
BJDX Price/Volume Stats
| Current price | $4.58 | 52-week high | $18.91 |
| Prev. close | $4.72 | 52-week low | $2.90 |
| Day low | $4.20 | Volume | 361,400 |
| Day high | $4.88 | Avg. volume | 437,143 |
| 50-day MA | $6.09 | Dividend yield | N/A |
| 200-day MA | $7.73 | Market Cap | 4.69M |
BJDX Stock Price Chart Interactive Chart >
BJDX Stock Summary
- BJDX has a higher market value than only 4.2% of US stocks; more precisely, its current market capitalization is $8,500,739.
- BLUEJAY DIAGNOSTICS INC's stock had its IPO on November 10, 2021, making it an older stock than just 2.02% of US equities in our set.
- The volatility of BLUEJAY DIAGNOSTICS INC's share price is greater than that of 99.89% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to BJDX, based on their financial statements, market capitalization, and price volatility, are KLIC, HCWB, ICCC, ADTN, and PALT.
- To check out BLUEJAY DIAGNOSTICS INC's SEC filings, go to the company's page on browse-edgar?action=getcompany&CIK=0001704287.
BJDX Valuation Summary
- BJDX's price/earnings ratio is -0.7; this is 102.49% lower than that of the median Healthcare stock.
- BJDX's EV/EBIT ratio has moved up 75.6 over the prior 21 months.
Below are key valuation metrics over time for BJDX.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| BJDX | 2023-07-26 | 29.3 | 0.8 | -0.7 | -0.1 |
| BJDX | 2023-07-25 | 30.5 | 0.8 | -0.8 | -0.1 |
| BJDX | 2023-07-24 | 35.3 | 1.0 | -0.9 | -0.3 |
| BJDX | 2023-07-21 | 24.9 | 0.7 | -0.6 | 0.0 |
| BJDX | 2023-07-20 | 21.3 | 0.6 | -0.5 | 0.1 |
| BJDX | 2023-07-19 | 22.1 | 0.6 | -0.6 | 0.1 |
Bluejay Diagnostics, Inc. (BJDX) Company Bio
Bluejay Diagnostics, Inc., an in-vitro diagnostic company, develops, manufactures, and markets minimally invasive point-of-care (POC) diagnostics tests and devices for infectious disease, inflammation, and oncology markets in the United States. It is developing Symphony biomarker detection platform for the detection of sepsis, cancer, cardiac ishcemia, and congestive heart failure. The company also offers ALLEREYE diagnostic test, a POC device for the diagnosis of allergic conjunctivitis. It has a collaboration agreement with Toray Industries, Inc. to develop a point of care test for covid-19 patient triage; and a research and development agreement with Naval Medical Research Center to develop lateral flow rapid test for diagnosis of various tick-borne diseases, including Lyme disease. Bluejay Diagnostics, Inc. was incorporated in 2015 and is headquartered in Acton, Massachusetts.
Latest BJDX News From Around the Web
Below are the latest news stories about BLUEJAY DIAGNOSTICS INC that investors may wish to consider to help them evaluate BJDX as an investment opportunity.
BJDX: FDA Meeting Confirms PathwayBy John Vandermosten, CFA NASDAQ:BJDX READ THE FULL BJDX RESEARCH REPORT 2Q:23 Financial and Operational Results Since our May initiation of Bluejay Diagnostics, Inc. (NASDAQ:BJDX), the company has regained compliance with the NASDAQ minimum bid price requirement following a reverse share split on July 24th. Bluejay is preparing to complete its pivotal trial and pursue a 510(k) FDA regulatory |
Bluejay Diagnostics Announces $1.59 Million Registered Direct Offering Priced At-The-Market under Nasdaq RulesACTON, Mass., Aug. 25, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, today announced that it has entered into a definitive agreement for the purchase and sale of 216,000 shares of the Company’s common stock at a purchase price of $7.365 per share of common stock in a registered direct offering priced at-the-mar |
Bluejay Diagnostics Announces Clinical Update and Reports Second Quarter 2023 Financial ResultsACTON, Mass., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, announced financial results for the six months ended June 30, 2023. “We continued to limit our cash burn during the quarter while executing our clinical strategy for the Symphony IL-6 test and are confident that our planned clinical and analyt |
Bluejay Diagnostics Regains Compliance with Nasdaq Minimum Bid Price RequirementACTON, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical technology company developing rapid diagnostics on its Symphony platform to improve patient outcomes in critical care settings, announced today that on August 8, 2023, it received a notification letter (the "Notification Letter") from the Listing Qualifications Department of The Nasdaq Stock Market LLC ("Nasdaq") notifying the Company that it had regained compliance wi |
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on FridayIt's time to start the day final of trading this week with an overview of the biggest pre-market stock movers on Friday morning! |
BJDX Price Returns
| 1-mo | -40.75% |
| 3-mo | 4.09% |
| 6-mo | -47.95% |
| 1-year | -72.53% |
| 3-year | N/A |
| 5-year | N/A |
| YTD | -39.72% |
| 2022 | -85.16% |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...